The Hive

The Hive is an innovation initiative for biotech and pharmaceutical start-ups, committed to promoting collaboration and inspiration across the Pharma & Life Sciences industry by providing an opportunity for participating companies to advance their research, and for others to learn from their experiences. The goal of The Hive is to help foster the discoveries that happen in these early-stage, start-up environments, ensuring that the route to market for new innovations is accelerated.

The Hive

The six participating companies – the second intake of start-ups to The Hive –  were specially selected for their commitment to cutting-edge science in emerging areas of research. All six demonstrate significant potential to impact how future treatments are researched and developed. As members of The Hive, each company will receive support, complimentary training, and access to Elsevier’s suite of R&D solutions for 18 months to support their groundbreaking and innovative work in some of the hottest research areas.

Enter your email address to follow The Hive and get the latest updates on participants and milestones – followed by the email address submission box.

Questions, comments or inquiries about The Hive? Send us a message.

Meet the participants

Exemplifying the fresh, innovative and agile world of R&D that is taking place outside the walls of Big Pharma, our four participants have the potential to change the industry’s landscape and improve the lives of patients. Discover the six companies selected to take part in The Hive and meet the people who make them tick.


4P-Pharma - thumbnail | Elsevier

4P-Pharma, from France, bridges the gap between academic discoveries and the pharma industry, helping to mature early-stage technologies from the drug discovery level to clinical phase and commercialization. The company was created in response to the urgent need to increase the number of innovative therapeutics entering the developing drug pipeline for cancer and inflammatory diseases.

Read more about 4P-Pharma

Beacon Discovery

Beacon Discovery - thumnail | Elsevier

Beacon Discovery, from San Diego, CA, USA, comprised of a group of scientists who have worked together for more than a decade, leverages academic and pharma partnerships to advance research around translating G-Protein Coupled Receptors (GPCRs) into new therapeutics. The company’s mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic.

Read more about Beacon Discovery


Exscientia - thumbnail | Elsevier

Exscientia, from Scotland, UK, uses systems driven by Artificial Intelligence to actively learn best practices from vast repositories of discovery data, and design millions of novel, project-specific compounds. The company – the first to automate drug design – is at the forefront of small molecule drug discovery.

Read more about Exscientia

LegoChem Biosciences

LegoChem Biosciences - thumbnail | Elsevier

LegoChem Biosciences, from South Korea (the first Hive participant from Asia); with its expertise in medicinal chemistry, develops next generation Antibody-Drug Conjugates (ADC) utilizing its proprietary ADC platform ConjuAll TM, providing solutions for site-specific conjugation, linker stability and efficient payload release—which are three major unmet needs in ADC development.

Read more about LegoChem Biosciences

Sigilon Therapeutics

Sigilon Therapeutics - thumbnail | Elsevier

Sigilon Therapeutics, from Cambridge, MA, USA, develops treatments based on a platform enabling a new therapeutic modality -- immune-privileged living therapeutic implants -- for chronic diseases including hematologic, enzyme deficiency, endocrine and metabolic disorders. The aim of these implants is to provide long-term, more natural control for diseases that are currently treated with intermittent injection or infusion in order to restore health and improve quality of life.

Read more about Sigilon Therapeutics

Unum Therapeutics

Unum Therapeutics - thumbnail | Elsevier

Unum Therapeutics, from Cambridge, MA, USA, is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products based on its universal Antibody-Coupled T-cell Receptor (ACTR).  When combined with an antibody that recognizes a target on the surface of tumor cells, the ACTR receptor can direct an individual’s T-cells to kill the tumor. Unlike other approaches (such as CAR-T or TCR), Unum’s therapy is not restricted to a particular target and may be used in many different cancer types.

Read more about Unum Therapeutics

Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by The Hive participants


Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more about Reaxys
Get started with Reaxys

Reaxys Medicinal Chemistry

Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more about Reaxys Medicinal Chemistry
Get started with Reaxys Medicinal Chemistry


Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase
Get started with Embase


Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more about PharmaPendium
Get started with PharmaPendium

Pathway Studio

Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio
Get started with Pathway Studio


Enable researchers to more effectively and efficiently search authoritative, full-text scientific, technical and health content through the use of smart, intuitive functionality.
Learn more ScienceDirect
Get started with ScienceDirect


Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peer-reviewed literature, including tools to track, analyze and visualize research.
Learn more about Scopus
Get started with Scopus